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DOI 10.1016/j.ccr.2009.12.043SUMMARYActivated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier in early cancer
development, at least in part, via an oncogene-evoked DNA damage response (DDR). In contrast, Myc
activation—although producing a DDR as well—is known to primarily elicit an apoptotic countermeasure.
Using the Em-myc transgenic mouse lymphoma model, we show here in vivo that apoptotic lymphoma cells
activate macrophages to secrete transforming growth factor b (TGF-b) as a critical non-cell-autonomous
inducer of cellular senescence. Accordingly, neutralization of TGF-b action, like genetic inactivation of the
senescence-related histone methyltransferase Suv39h1, significantly accelerates Myc-driven tumor devel-
opment via cancellation of cellular senescence. These findings, recapitulated in human aggressive B cell
lymphomas, demonstrate that tumor-prompted stroma-derived signals may limit tumorigenesis by feedback
senescence induction.INTRODUCTION
Mitogenic oncogenes provoke checkpoint-mediated cellular
countermeasures such as apoptosis or premature senescence,
a terminal G1 arrest involving the p53 and p16INK4a tumor
suppressors that is characterized by typical transcriptional,
biochemical and morphological alterations (Campisi and
d’Adda di Fagagna, 2007; Hemann and Narita, 2007). RAS- or
BRAF-initiated senescent lesions in vitro and in vivo exhibit
chromatin changes that include the transcriptionally repressive
trimethylation mark at H3K9 (H3K9me3) and focal enrichmentSignificance
Cancer entities with constitutive Myc expression, among them
of apoptosis. So far, cellular senescence as another oncog
RAS/BRAF-driven scenarios, but not as a bona fide Myc-evok
Em-myc transgenic mouse lymphoma model and presenting su
samples, this study establishes a network of tumor/host imm
a paracrine response in non-malignant bystanders that limits
the relevance of oncogene-induced senescence to Myc-driven
utor and potential therapeutic target in this process.
262 Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc.of HP1 proteins for which H3K9me3 provides a docking site
(Bartkova et al., 2006; Braig et al., 2005; Collado et al., 2005;
Lachner et al., 2001; Michaloglou et al., 2005; Narita et al.,
2003). Mechanistically, hypophosphorylated retinoblastoma
(Rb) protein, bound to growth-promoting E2F transcription
factors, may recruit H3K9 methyltransferase activities such as
Suv39h1 to direct heterochromatinization to the vicinity of E2F-
responsive promoters, thus silencing S-phase genes (Narita
et al., 2003). Increasing evidence points towards an oncogene-
induced DDR as critical upstream trigger of the senescence
program (Bartkova et al., 2006; Di Micco et al., 2006; Malletteaggressive B cell lymphomas, typically display high levels
ene-inducible safeguard program has been recognized in
ed anticancer mechanism. Utilizing the genetically tractable
pportive evidence from human aggressive B cell lymphoma
une cell interactions in which apoptotic tumor cells launch
lymphomagenesis by cellular senescence. Our data expand
cancers, and highlight the tumor stroma as a critical contrib-
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Myc Induces Senescence via a DDR and Stromal TGF-bet al., 2007). Indeed, Myc and RAS oncogenes cause DNA
damage by inducing reactive oxygen species (ROS) and gener-
ating stalled DNA replication intermediates (Di Micco et al., 2006;
Lee et al., 1999; Reimann et al., 2007; Vafa et al., 2002).
However, both prototypic oncogenes produce very different
outcomes—i.e., predominantly cellular senescence following
RAS/BRAF and apoptosis in response to Myc activation—
when activated in primary cells in vitro (Evan et al., 1992; Serrano
et al., 1997).
So far, there has been no clear evidence that Myc induction in
primary cells may cause senescence under physiological condi-
tions in vitro or in vivo (Feldser and Greider, 2007; Grandori et al.,
2003; Guney et al., 2006). One cell-autonomous explanation for
Myc’s primarily proapoptotic action might be that Myc favors
apoptosis over arrest by influencing p53-dependent transactiva-
tion processes in response to DNA damage (Seoane et al., 2002).
The purpose of this study was to determine the contribution of
cellular senescence as a tumor-suppressive mechanism in a
transgenic mouse model of Myc-driven lymphomagenesis remi-
niscent of aggressive B cell lymphomas in humans. Given the
well-established predominantly apoptotic response to Myc acti-
vation in primary cells in vitro, we specifically aimed to dissect
cell-autonomous and non-cell-autonomous components of
Myc-related senescence in vivo.
RESULTS
Suv39h1-Dependent Cellular Senescence Limits
Myc-Induced Lymphomagenesis
To determine the role of cellular senescence in Myc-driven
tumorigenesis, we studied the impact of senescence-compro-
mising Suv39h1 loss in Em-myc transgenic mice (Adams et al.,
1985; Braig et al., 2005), where genetic disruption of apoptosis
strongly promotes B cell lymphomagenesis (Egle et al., 2004;
Schmitt et al., 2002b; Strasser et al., 1990). Mice that lacked
one or both Suv39h1 alleles developed lymphomas significantly
faster than mice without a targeted defect at the Suv39h1 locus
(p < 0.0001 for either comparison, Figure 1A). Moreover, lym-
phomas that formed in Suv39h1+/ female mice invariably lost
expression of the X-chromosomally encoded Suv39h1 tran-
script, thereby explaining the indistinguishable tumor onset
in Suv39h1+/ and Suv39h1 (i.e., Suv39h1/y male and
Suv39h1/ female) mice (Figure 1A, insert). Importantly, the
frequency of apoptosis measured as TUNEL reactivity, a hallmark
of Myc-driven lymphomas, was virtually identical in Suv39h1-
deficient lymphomas when compared to control lymphomas
(i.e., those that arose in Em-myc mice without a targeted
Suv39h1 lesion; Figure 1B). Furthermore, control and Suv39h1-
deficient lymphomas presented with indistinguishable gross
pathology, formed at comparable stages of B cell development,
both expressed Suv39h2 transcripts, and displayed similar near-
normal chromosome counts, unlike the previously reported chro-
mosome-missegregated B cell lymphomas that form in the
absence of both Suv39h1 and Suv39h2 alleles in nontransgenic
mice (Peters et al., 2001) (data not shown). Thus, neither compro-
mised apoptosis nor overt aneuploidy accounts for the acceler-
ated lymphoma onset in Suv39h1-deficient Em-myc mice.
To directly assess oncogene-induced senescence as a poten-
tial component of delayed lymphoma manifestation, senes-cence-associated b-galactosidase (SA-b-gal) activity (Dimri
et al., 1995) was analyzed in Suv39h1-deficient and control
lymphomas. Virtually none of the cells in theSuv39h1 lymphoma
sections, but an average of about 14% of the control lymphoma
cells, stained (often in a focal pattern) positive for SA-b-gal
(P < 0.001; Figures 1B and 1C; see Figures S1A and S1B
available online for further evidence that senescent cells are
indeed B lymphoma cells). Moreover, coanalysis of the prolifer-
ation marker Ki67 or bromodeoxyuridine (BrdU) incorporation,
indicating DNA synthesis, with SA-b-gal or H3K9me3 stain-
ing confirmed the growth-arrested nature of SA-b-gal- or
H3K9me3-positive cells (Figure 1D). Immunoblot analyses of
bulk lymph node lysates indicated no differences in the expres-
sion levels of Myc and the cell-cycle inhibitor p21CIP1 between
control and Suv39h1 lymphomas, while significant amounts of
hypophosphorylated/G1-phase Rb and of H3K9me3 were only
found in control lymphomas, which also displayed slightly
reduced levels of the CDK4/6 inhibitor p16INK4a and the E2F
target cyclin A (Figure 1E). Other histone modifications such as
H3K4me3, acetylated H3K9, H3K27me3, or H4K20me3 ap-
peared globally unaffected by Suv39h1 status (data not shown),
underscoring the specific role of the Suv39h1-mediated
H3K9me3 mark in the senescence process. Moreover, spleen
samples derived from young, lymphoma-free Em-myc mice
(termed ‘‘preneoplastic,’’ albeit consisting of Myc-overexpress-
ing normal B cells) as compared with spleen sections from non-
transgenic mice exhibited signs of cellular senescence in a
strictly Myc- and Suv39h1-dependent fashion, indicating that
oncogene-related senescence may delay tumorigenesis already
at a premalignant state (Figure S1C). Thus, aggressive Myc-
driven lymphomas develop and manifest with a significant frac-
tion of cells that lack any proliferative activity and display marks
of cellular senescence.
All Myc-lymphomas developing in Suv39h1+/;p53+/ or
Suv39h1;p53+/ backgrounds selected against the remaining
p53 wild-type allele (12/12 cases tested ‘‘p53-null’’; Figure 1F),
as known from lymphomas forming in Em-myc;p53+/ mice
(Schmitt et al., 1999), and, thus, against p53-dependentapoptosis.
Suv39h1 RNA expression was mostly retained in Suv39h1+/;
p53+/-derived lymphomas (7/9 cases tested; Figure 1F), indi-
cating that p53 loss coablates an apoptosis-independent
tumor-suppressive function otherwise governed by Suv39h1.
Accordingly, additional inactivation of Suv39h1 produced no
furtheraccelerationofEm-myc lymphomagenesis in ap53+/back-
ground (data not shown). Notably, and different from p53-null
lymphomas, DDR-defective ATM/ lymphomas displayed only
a partial reduction of the senescent fraction at manifestation (Fig-
ure 1G and Figure S1D, showing, in addition, control lymphoma-
comparable senescence in p16INK4a-deficient INK4a/ and
p21CIP1-deficient CIP1/ lymphomas, but compromised senes-
cence in ARF/ lymphomas). Taken together, Myc-induced
senescence presents in vivo as a p53-, Suv39h1-, and partly
ATM-dependent program that complements apoptosis as an anti-
oncogenic safeguard mechanism in Em-myc lymphomagenesis.
Activated Myc Promotes ATM/p53-Dependent
Senescence
Myc activation is known to produce marks of DNA damage
in vivo (Reimann et al., 2007), at least in part via ROS, whichCancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc. 263
Figure 1. Suv39h1-Dependent Senescence Attenuates Myc-Driven Lymphomagenesis
(A) Latencies to palpable lymphoma manifestation in Em-myc transgenic mice (control lymphoma, n = 93, black), in Em-myc;Suv39h1+/ (n = 41, red), and in
Em-myc;Suv39h1 mice (n = 31, orange). Insert: Suv39h1 mRNA expression by RT-PCR analysis of short-term cultured lymphomas derived from Suv39h1+/
mice (n = 4) with a Suv39h1+/+ derived lymphoma for comparison; TBP as an internal control.
(B) Growth-related parameters, i.e., apoptosis by TUNEL reactivity, and senescence by SA-b-gal staining in lymph node sections obtained at manifestation from
Em-myc control or Suv39h1 lymphomas (representative photomicrographs from at least nine samples per genotype tested).
(C) Percentages of SA-b-gal-positive cells (as in B) in individual control (n = 25) and Suv39h1 (n = 9) lymphomas. Horizontal lines represent the mean percentage
of each group. Note that low-level SA-b-gal-positive cases in the control group are enriched for spontaneously p53 mutant or homozygously INK4a/ARF-deleted
lymphomas (Schmitt et al., 1999) (data not shown).
(D) Percentages of Ki67-positive (red) and BrdU-positive cells (brown; note the mutually exclusive SA-b-gal-costaining [blue]) in situ, and quantification of
H3K9me3high/Ki67low cells (arrow-marked gate, representing senescent cells) by flow cytometry in control and Suv39h1 lymphomas.
(E) Immunoblot analyses of the indicated proteins in individual control (lanes 1–4) and Suv39h1 (lanes 5–8) lymphoma cell lysates with a-tubulin as a loading
control (arrow indicates the hypophosphorylated [hypo-P] Rb band representing cells in G1).
(F) Genomic status of the p53 locus by allele-specific PCR (top) and expression status of Suv39h1 transcripts by RT-PCR (bottom; TBP as an internal control)
analyses of short-term cultured lymphoma cells that were isolated from mice of the indicated genotypes. Extracts from p53+/ and p53/ MEFs as controls.
(G) Frequencies of SA-b-gal-positive cells in Em-myc lymphoma cryosections of the indicated genotypes at diagnosis (control and Suv39h1 as in B, at least four
cases per genotype tested). All numbers indicate the mean percentages of positive cells ± SD; *p < 0.05. All scale bars represent 50 mm (identical magnification
throughout the panel). See also Figure S1.
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Notably, Suv39h1 had no impact on g-H2AX-marked DNA
lesions and the DDR signature in preneoplastic Em-myc trans-
genic B cells, or in lymphoma cells exposed to g-irradiation
(Figure S2A-C). However, in contrast to wild-type B cells, primary
B cells lacking the DDR mediators ATM or p53 largely failed—like
Suv39h1-deficient B cells—to senesce in response to acute Myc
overexpression in vitro (Figure 2A. If senescence detected in
control lymphomas in situ is initiated via a Myc-evoked DDR,264 Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc.then genetic or pharmacological interference with the DDR
should impact on the senescence response. Comparable to
theATM/ scenario (Figure 1G), exposure of Em-myc transgenic
mice to the ROS scavenger N-acetyl-cysteine (NAC) or to the
ATM/ATR inhibitor caffeine, both of which blunt an oncogene-
evoked DDR in vivo (Bartkova et al., 2006; Reimann et al.,
2007), resulted in a profound, albeit only partial reduction of
senescent lymphoma cells in situ (Figure S2D-F, also showing
that ROS levels are Myc, but not Suv39h1 dependent).
Figure 2. Myc Has p53-Dependent Prosenescent Potential
(A) Relative fractions of SA-b-gal-positive nontransgenic primary B cells of the indicated genotypes 10 days after stable transduction with a Myc construct
(R 80% of the cells infected; dead cells [around 40% initial apoptosis] were removed, resulting in about 5% senescent cells in the wild-type population) as
compared with an empty vector.
(B) Growth parameters (i.e., Ki67, S-phase fraction by BrdU/PI [arrow], and SA-b-gal frequencies) in bcl2-infected nontransgenic B cells (left) and Em-myc;
p53ERTAM/()/bcl2 lymphoma lymphomas (right) in which functional p53 is restored in response to 4-OH-tamoxifen (4-OHT; solvent serving as the negative
control) treatment for 6 days. Scale bar represents 20 mm (identical magnification throughout the panel).
(C) Acute induction of functional p53 by administration of tamoxifen in mice bearing lymphomas as in (B); stained for BrdU labeling, Ki67 reactivity (H3K9me3:
10.7% ± 3.5 [solvent] versus 39.0% ± 6.2 [tamoxifen]), apoptosis-indicating cleavage (cl.) of caspase 3, and SA-b-gal activity. Scale bar represents 50 mm
(identical magnification throughout the panel).
(D) SA-b-gal frequencies in lymphomas as in (B) exposed in vitro for 6 days to 4-OHT (or a solvent as negative control) with no additional compound, or 5 mM of the
ATM/ATR inhibitor caffeine (caf), 5 mM of the ROS scavenger N-acetyl-cysteine (NAC), or both. At least three cases each in all these experiments; all numbers
indicate the mean percentages of positive cells ± SD; *p < 0.05. See also Figure S2.
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Myc Induces Senescence via a DDR and Stromal TGF-bTo directly address the cell-autonomous potential of Myc to
drive senescence, we tested whether a conditional p53 moiety
would suffice to convert constitutive Myc signaling into a robust
senescence response in apoptosis-incapable cells. To this end,
we employed Em-myc mice carrying a 4-OH-tamoxifen (4-OHT)-
inducible p53ERTAM knockin allele, encoding a p53-estrogen
receptor fusion protein that is inactive in the absence of 4-OHT
(Martins et al., 2006). Expectedly, Em-myc;p53ERTAM/+ lym-
phomas that arose in the absence of 4-OHT typically selected
against the remaining p53 wild-type allele (termed p53ERTAM/();
5/5 cases tested (data not shown and Martins et al., 2006),
thereby generating p53-null lymphomas in which p53 activity is
restorable upon provision of 4-OHT (Figure S2G). Constitutively
Myc-expressing and bcl2-transduced (and, thus, apoptosis-pro-
tected) lymphoma cells quantitatively entered senescence
following exposure to 4-OHT in vitro, whereas nontransgenic
Bcl2-protected p53ERTAM-expressing B cells lacked such a re-
sponse (Figure 2B). Similarly, senescence was strongly induced
when mice harboring Em-myc;p53ERTAM/()/bcl2 lymphomaswere exposed to tamoxifen in vivo (Figure 2C). Importantly,
pharmacological scavenging of ROS or ablation of the DDR
attenuated and, when combined, almost completely blocked
the senescence induction of Em-myc;p53ERTAM/()/bcl2 lym-
phoma cells in response to 4-OHT in vitro (Figure 2D). Thus,
acute overexpression of Myc in primary cells or p53 reactivation
in the presence of constitutive Myc signaling unmasks the cell-
autonomous, DDR-mediated prosenescent capability of Myc.
TGF-b Induces Senescence of Myc-Driven Lymphoma
Cells
Because neither ATM deficiency nor pharmacological DDR
ablation was sufficient to fully abrogate senescence of Myc-
driven lymphoma cells in vivo, we aimed to identify an additional
stimulus that may complement oncogene-induced DDR signaling
in vivo. Genome-wide transcriptional profiling of whole lymph
node RNA preparations from Suv39h1-proficient versus
Suv39h1-deficient Em-myc lymphomas identifiedTGF-b-induced
gene (Tgfbi; also known as Big-h3, b-ig H3, or keratoepithelin) asCancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc. 265
Figure 3. TGF-b Induces Suv39h1-Dependent Cellular Senescence in Myc-Driven Lymphomas
(A) Focal TGF-b1 detected by immunostaining (left) and costaining (right) for TGF-b1 (red) and Ki67 (blue) in control versus Suv39h1 lymphomas in lymph node
sections in situ (representative photomicrographs). Inserts show TGF-b1-rich areas at higher magnification, and percentages reflect the fraction Ki67-positive
cells within those areas (n = 3 samples each). Scale bar represents 50 mm (identical magnification throughout the panel).
(B) Growth curve analyses of freshly isolated and stably bcl2-infected control and Suv39h1 lymphoma cells exposed to the indicated concentrations of TGF-b1
(100 pM [red], 1000 pM [green]) or left untreated (black); n = 5 each. Inserts show untreated versus TGF-b1-exposed (100 pM; day 5) lymphoma cell cytospin
preparations assayed for SA-b-gal (top; 50.0% ± 13.2 [control] versus 3.3% ± 2.9 [Suv39h1] for TGF-b1) and H3K9me3 reactivity (bottom; in red with DAPI
as counterstain; 35.4% ± 14.4 [control] versus 0.4% ± 0.1 [Suv39h1] for TGF-b1). Note the comparable proliferative capacities of Suv39h1-proficient and
Suv39h1-deficient lymphoma cells in the absence of TGF-b1 treatment. Scale bar represents 10 mm (identical magnification throughout the panel).
(C) Immunoblot analysis of cyclin A protein levels (a-tubulin as a loading control) in lymphomas as in (B) with or without preceding exposure to TGF-b1 (100 pM
for 5 days).
(D) Relative growth of Bcl2-expressing lymphoma cells of the indicated genotypes after 5 days of exposure to TGF-b1 (100 pM) versus untreated (as in [B]).
At least three cases each. Error bars denote SD; *p < 0.05. See also Figure S3.
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Myc Induces Senescence via a DDR and Stromal TGF-bthe most strongly differentially upregulated transcript. Tgfbi, a
TGF-b target, was expressed 3.9-fold higher in Suv39h1
lymphomas, and encodes a secreted protein with cytostatic
potential that was previously linked to cellular senescence (Dok-
manovic et al., 2002) (see Experimental Procedures for details
and the confirmatory quantitative reverse transcriptase poly-
merase chain reaction [RQ-PCR] analysis in Figure S3A). We
found TGF-b1, known to induce cellular senescence in fibroblasts
(Lin et al., 2004), to be detectable in a multi-focal pattern in
lymphoma sections reminiscent of the distribution of SA-b-gal-
positive cells in control lymphomas (Figure 3A, compare to
Figure 1B). Importantly, costaining for the proliferation marker
Ki67 unveiled that in areas with abundant TGF-b1 significantly
less control cells were Ki67-positive when compared with
Suv39h1 lymphomas (Figure 3A). Thus, TGF-b correlates with a
cytostatic response selectively detectable in control lymphomas,
and high Tgfbi levels in Suv39h1 cells are suggestive of a down-
stream defect in a TGF-b-inducible senescence program.
We sought to directly test the potential of exogenous TGF-b1
to induce cellular senescence in a Suv39h1-dependent fashion
in Myc-driven lymphoma cells that were stably bcl2-transduced
to block apoptosis. TGF-b1 countered proliferation in a dose-
dependent manner and led to a complete growth arrest with
features of cellular senescence, i.e., SA-b-gal activity and266 Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc.H3K9me3 expression, in control, but not in Suv39h1 lymphoma
cells, whose growth behavior remained largely unaffected by
TGF-b1 treatment (Figure 3B). Lack of a cytostatic response in
Suv39h1 cells was not due to a primary defect in TGF-b receptor
signaling, because lymphoma cells of both genotypes exhibited
phosphorylation of the intracellular TGF-b1 mediators Smad2
and Smad3 following TGF-b1 treatment in vitro (Figure S3B). In
line with the transcriptionally repressive H3K9me3 mark selec-
tively induced in control lymphomas (Figure 3B), TGF-b1-treated
control lymphomas displayed reduced transcript levels of
numerous E2F target genes, including MCM7 or Cyclin A by
microarray analysis, as well as increased levels of transcripts
that encode for components of the heterochromatinization
machinery such as DNA methyltransferase 3B or HP1b (Fig-
ure S3C, and Figure 3C for cyclin A protein expression). The
mechanism by which TGF-b utilizes Suv39h1, presumably in
conjunction with Rb/E2F complexes (Laiho et al., 1990; Schwarz
et al., 1995; Spender and Inman, 2009), to induce senescence
appears to be indirect, because we were unable to detect a
physical interaction between Suv39h1 and Smad proteins
(Figure S3D). TGF-b1 was incapable of inducing p15INK4b or
p21CIP1 mRNA and protein expression in lymphomas indepen-
dent of their Suv39h1 status, probably because constitutive
Myc expression firmly represses these promoters via Miz-1
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Myc Induces Senescence via a DDR and Stromal TGF-b(Seoane et al., 2002; Spender and Inman, 2009) (Figure S3E, and
transcriptional levels by RQ-PCR, data not shown). Unlike g-irra-
diation, TGF-b1 treatment of lymphoid cells failed to produce
DNA lesions (Figures S3F and S3G), and was not accompanied
by elevated ROS levels either (data not shown). Of note, H2O2-
induced DNA damage, at levels comparable to DNA damage
evoked by oncogenic Myc, synergized with TGF-b to promote
cellular senescence (Figure S3G, compare with g-H2AX foci in
Figure S2A), as seen for Myc induction and TGF-b treatment in
MEFs (Figure S3H). Accordingly, DDR-defective ATM/
lymphomas senesced in response to TGF-b1 as control (or, like-
wise, p16INK4a- or p21CIP1-deficient) lymphomas did, whereas
p53-null lymphomas were expectedly refractory (Cordenonsi
et al., 2003) (Figure 3D). Hence, TGF-b promotes cellular senes-
cence without damaging DNA, but cooperatively with oncogene-
related DDR signaling in a Myc-primed and p53/Suv39h1-
dependent fashion.
Next, we aimed to identify the cellular source of the consider-
able amounts of TGF-b detectable in Em-myc lymphoma tissues.
Importantly, lymphoma cells did not secrete TGF-b1 above
culture medium background levels (Figure S3I). However, freshly
isolated lymphoma cells exhibited Smad3 phosphorylation
(Smad3-P), a mark of activated TGF-b signaling, whereas
Smad3-P was undetectable in freshly isolated preneoplastic
Em-myc transgenic B cells (Figure S3J; see also Figure S1C).
Likewise, no Smad3-P signal was found in nontransgenic B cells
following transduction with a Myc expression construct, indi-
cating that Myc per se is incapable of driving TGF-b expression.
Notably, the recently observed link between oncogene-induced
senescence and a senescence-reinforcing proinflammatory
secretory phenotype, termed ‘‘SASP’’ (Acosta et al., 2008;
Coppe et al., 2008; Kuilman et al., 2008; Wajapeyee et al.,
2008), raised the question of whether TGF-b1 might be a compo-
nent or a regulator of the SASP-related cytokines. However,
RQ-PCR analysis of a panel of SASP candidates in Myc-
lymphomas of various genotypes exposed to senescence-
inducing H2O2 or TGF-b1 unveiled substantial SASP induction
only in senescence-capable control lymphomas following
exposure to H2O2, but not to TGF-b1. Moreover, TGF-b1 itself
does not belong to the SASP signature of lymphoma cells, which
is different from fibroblasts that expressed increased amounts of
TGF-b1 upon g-irradiation or H2O2 (Figure S3K-M). In essence,
neither proliferating nor senescent lymphoma cells secrete
significant amounts of TGF-b, implying that TGF-b might be
provided by nonneoplastic bystander cells.
Apoptotic Lymphoma Cells Activate Macrophages
to Secrete Prosenescent TGF-b1
We considered lymphoma-infiltrating and lymphoma-activated
macrophages to serve as a non-cell-autonomous source of
TGF-b1 in vivo, because macrophages reportedly secrete
TGF-b1 upon phosphatidylserine (PS)-dependent ingestion of
apoptotic cells (Huynh et al., 2002; Savill and Fadok, 2000),
which are typically found at significant frequencies in Myc-driven
lymphomas (Figure 1B, and Figure S4A for the phenotypic char-
acterization of lymphoma-infiltrating macrophages). Indeed,
coculture of macrophages with PS-positive apoptotic, but not
with PS-negative proliferating, lymphoma cells resulted in
increased TGF-b1 secretion, as alternatively observed uponstimulation of macrophages with PMA (phorbol 12-myristate
13-acetate; Figure 4A and Figure S4B). Consistently, lymphomas
harboring a robust Bcl2-mediated apoptotic block (control/bcl2;
see also Schmitt et al., 2002b) presented with a much lower
frequency of both infiltrating macrophages and senescent cells
in vivo (Figure 4B and Figure S4C, see also Figure 1G and
Figure S1D for a correlation between senescent cells and
infiltrating macrophages in various lymphoma genotypes). The
nearly complete absence of senescent control;bcl2 lymphoma
cells in vivo despite their in vitro susceptibility to TGF-b-medi-
ated senescence (Figure 3B) underscores the importance of
non-cell-autonomous events such as attraction of macrophages
(Lauber et al., 2003) and their subsequent activation by apoptotic
lymphoma cells to secrete TGF-b1.
To further elucidate the prosenescent role of activated macro-
phages in vivo, we adoptively transferred PMA-stimulated Ana-1
macrophages into mice harboring Myc-driven lymphomas.
GFP-tagged Ana-1 cells homed to lymphoma sites, and their
presence correlated with enhanced TGF-b1 pathway activation
(i.e., Smad3-P), induction of the TGF-b target and senescence
indicator plasminogen activator inhibitor-1 (PAI-1), and, most
notably, with a substantial increment of senescent lymphoma
cells (Figure 4C, and Figures S4D and S4E). Conversely, sys-
temic depletion of macrophages by repetitive provision of lipo-
some-encapsulated clodronate (Aichele et al., 2003) significantly
lowered the number of lymphoma-infiltrating macrophages,
Smad3 activation (i.e., Smad3-P), and, most importantly, lym-
phoma cell senescence (Figure 4D, and Figures S4F and S4G;
for effects of pharmacological inhibition of TGF-b production
see Figures S4H–S4J).
To confirm the impact of TGF-b on senescence induction
in vivo, we sought to locally block its action by expressing a
soluble, secretable TGF-b1-neutralizing TGF-b type II receptor
extracellular domain (TbR-II-ED), thereby restricting TGF-b
inhibition to the vicinity of TbR-II-ED-expressing cells (Thomas
and Massague, 2005). Importantly, transplantation of Em-myc
transgenic hematopoietic stem cells stably transduced with
TbR-II-ED into lethally irradiated recipient mice resulted in
a profoundly accelerated onset of lymphomas (p < 0.0001); these
lymphomas virtually lacked Smad3 phosphorylation and dis-
played, despite unaffected macrophage frequencies, much
fewer senescent cells when compared with a mock-infected
cohort (Figure 4E and 4F and Figures S4K–S4M). Tumor latency
remained unchanged when the TbR-II-ED moiety was tested in
Suv39h1-deficient hematopoietic stem cells, indicating that
TGF-b-mediated apoptosis has no significant tumor-delaying
impact in this model (data not shown). Furthermore, when
matched pairs of primary lymphomas were propagated in
immunocompetent recipients, TbR-II-ED-expressing lymphomas
always formed with lower senescence frequencies than the cor-
responding empty vector samples (Figure 4G). Thus, selective
ablation of TGF-b action reduces lymphoma cell senescence in
tumor development and in otherwise genetically identical
lymphoma aliquots during tumor expansion in vivo. Importantly,
these results, like the sharply reduced senescence frequency in
Bcl2-protected lymphomas in vivo (Figure 4B), clarify that the
non-cell-autonomous induction of senescence is quantitatively
substantially more relevant than the cell-autonomous signaling
cascade into senescence (as addressed in Figure 2).Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc. 267
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Figure 4. Environmental TGF-b, as Secreted by Apoptotic Lymphoma Cell-Activated Macrophages, Accounts for Lymphoma Cell
Senescence In Vivo
(A) Relative induction of TGF-b1 protein levels at 48 hours by enzyme-linked immunosorbent assay in cell culture supernatants of primary peritoneal macrophages
(pMP) alone or after coculture with Em-myc;p53ERTAM/() lymphomas exposed for 20 hours to 4-OHT or solvent (n = 3 each; relative to the normalized medium-
corrected ‘‘pMP solvent’’ value). Note that 4-OHT, but not solvent, quantitatively produced PS-positive apoptotic lymphoma cells (Figure S4B). Relative induction
of TGF-b1 secretion at 48 hours by PMA-stimulated (200 ng/ml) Ana-1 macrophages for comparison (in triplicate).
(B–D) Quantification of macrophage infiltration (Mac) measured by F4/80 immunostaining (numbers indicating average macrophage count per high-power field)
and of senescence (Sen) assessed by SA-b-gal staining (B) in apoptosis-blocked Bcl2-expressing lymphomas, generated by retroviral bcl2 transfer (or an empty
vector as control) into Em-myc transgenic fetal liver cells and their subsequent propagation in lethally irradiated recipients, at manifestation, (C) following adoptive
transfer of PMA-stimulated Ana-1 macrophages (as in A) by intravenous transfer into control lymphoma bearing mice, and (D) after systemic monocyte/macro-
phage depletion by liposome-encapsulated clodronate or empty liposomes for comparison.
(E) Tumor latencies, stratified by lymphoma GFP expression, in lethally irradiated recipients of Em-myc transgenic fetal liver cells stably transduced with the
MSCV-TGF-b receptor type II ecto domain-IRES-GFP (TbR-II-ED/GFP) retrovirus (TbR-II-ED/GFP-positive, n = 9, green, versus mock/GFP-negative,
n = 11, black).
(F) Quantification of macrophage infiltration and senescence, assessed as in (B-D), in TbR-II-ED/GFP-expressing versus mock-infected lymphomas as in (E).
Note that around 10%–20% of the overall senescence frequency can be attributed to the cell-autonomous component (see also B).
(G) Matched pair quantification of cellular senescence in individual control lymphomas (n = 6) infected with the TbR-II-ED/GFP or an empty/GFP retrovirus that
formed after sorting and transplantation of GFP-expressing cells.
(H) Senescence frequencies of bcl2-infected control lymphoma cells exposed—in the presence or absence of the TGF-b receptor type I inhibitor SD-208 (TGFR-I;
500 nM) —to pMP that were either native or cocultivated with Em-myc;p53ERTAM/() lymphomas plus solvent or 4-OHT for 48 hours. All experiments in this figure
represent at least three independent samples each; all numbers indicate mean values ± SD; *p < 0.05; n.s., indicates not significant. See also Figure S4.
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Myc Induces Senescence via a DDR and Stromal TGF-bUltimately, we aimed to dissect the sequential process of
lymphoma cell apoptosis-induced macrophage-derived TGF-b
action on lymphoma cell senescence in a single in vitro experi-
ment. To this end, we coincubated Bcl2-protected lymphoma
cells with macrophages, which were activated by exposure to
apoptotic lymphoma cells beforehand, with or without a phar-
macological TGF-b receptor type I inhibitor (TGFR-I). Indeed,
only apoptotic body-activated macrophages produced a more
than 3-fold increase of SA-b-gal-positive lymphoma cells that
was largely abolished in the presence of the TGFR-I (Figure 4H
and Figure S4N). Therefore, TGF-b secreted by macrophages
upon their activation by apoptotic lymphoma cells indeed
acts as a critical stroma-derived inducer of lymphoma cell
senescence.268 Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc.To test whether the proposed mouse model-deduced mecha-
nism of non-cell-autonomous senescence induction may apply
to human aggressive B cell lymphomas as well, we analyzed its
central components in a panel of 30 diffuse large B cell lymphoma
samples. The panel was subdivided based on Ki67 immunoreac-
tivity into a very high proliferation (Ki67hi; R 80% Ki67-positive
cells) group and a lower proliferation (Ki67lo; < 80% Ki67-positive
cells) group. Indeed, Ki67lo samples exhibited a significantly
higher frequency of H3K9me3-positive cells, indicative of cellular
senescence in paraffin-embedded sections that cannot be
examined for enzymatic SA-b-gal activity (Figure 5A and 5B).
Importantly, the Ki67lo group also presented with a higher frac-
tion of apoptotic cells, more lymphoma-infiltrating macrophages,
and a stronger reactivity for the TGF-b signaling mediator
Figure 5. Human Diffuse Large B Cell Lymphomas (DLBCL) Display Features Consistent with the Model of Non-Cell-Autonomous
TGF-b-Mediated Cellular Senescence
(A) Two DLBCL cases reflecting a highly (Ki67hi; samples withR 80% Ki67-positive cells) and a less intensely proliferating (Ki67lo; samples with < 80% Ki67-
positive cells) subgroup also stained for apoptosis (cleaved Caspase 3), macrophage infiltration (CD68), TGF-b pathway activation (i.e., Smad3-P), and cellular
senescence (i.e., H3K9me3 as a surrogate marker). Representative photomicrographs of a total of 30 cases analyzed. Scale bar represents 100 mm (identical
magnification throughout the panel).
(B) Quantitative assessment of cleaved (cl.) Caspase 3, CD68, Smad3-P, and H3K9me3 in the Ki67 low versus high groups (Ki67lo, n = 19, Ki67 reactivity
68.7% ± 6.6 versus Ki67hi, n = 11, 88.9% ± 5.7; p < 0.001). All comparisons are highly statistically significant (i.e., p < 0.001), except a trend (p = 0.07) for
cl. caspase 3. All numbers indicate mean values ± SD; *p < 0.05. Notably, no clear association of the Ki67 status with the germinal center (GC) B cell-of-origin
status (GCB versus non-GCB by immunostaining [Hans et al., 2004], data not shown) was observed.
(C) Model of oncogene-initiated cell-autonomous and non-cell-autonomous cellular senescence in aggressive B cell lymphomas, as concluded from Em-myc
mouse lymphoma data.
Cancer Cell
Myc Induces Senescence via a DDR and Stromal TGF-bSmad3-P (Figure 5B). Thus, these data strongly suggest that
environmentally cocontrolled tumor cell senescence plays an
important growth-restraining role in human aggressive B cell
lymphomas as well.
DISCUSSION
Our data establish a model of senescence induction in an onco-
genic context where the primary cellular response to the driving
oncogene is overt apoptosis, not senescence. Elegant work
elucidating signaling cascades involved in RAS-, BRAF-, or
MEK-type oncogene-induced senescence demonstrated that
an oncogene-evoked DDR (Bartkova et al., 2006; Di Micco
et al., 2006; Mallette et al., 2007), a global negative feedback
response attenuating RAS effector signaling (Courtois-Cox
et al., 2006), and, most recently, proinflammatory cytokines
acting as reinforcing networks (Acosta et al., 2008; Coppe
et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008)
contribute to the senescence phenotype. However, all of these
studies view senescence as a cell-autonomous phenomenonin which, if at all, cellular interactions or secreted factors promote
the senescent arrest in a homotypic self-amplifying way. We
report here an oncogene-initiated but non-cell-autonomous
route into senescence. This process depends on the activation
of TGF-b1-secreting nonneoplastic cells as a critical interme-
diate step, linking Myc-provoked cell-autonomous apoptosis
to the subsequent senescence induction of a significant propor-
tion of the remaining tumor cells by the stromal cytokine
(Figure 5C). Hence, our data demonstrate that apoptosis and
senescence are not simply two context-dependent choices of
cellular stress responsiveness, but that they can be enforced in
an interdependent fashion on the organismic level. In this regard,
disrupted DNA damage signaling might not only compromise
cell-autonomous induction of cellular senescence (Figures 1G
and 2D and Figures S2E and S2F), but might also anticipate
impaired macrophage-related senescence due to reduced pri-
mary apoptosis. Importantly, DDR-defective tumor cells remain
susceptible to non-DNA-damaging prosenescent stimuli that
might be therapeutically exploited in the future. Moreover, our
data underscore why p53 inactivation—blocking apoptosis,Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc. 269
Cancer Cell
Myc Induces Senescence via a DDR and Stromal TGF-bpreventing macrophage attraction, and rendering the cell insen-
sitive to TGF-b-induced senescence—is a particularly efficient
way to escape Myc-related senescence.
We would like to emphasize that 12%–20% senescent cells,
which were detectable in control lymphomas at diagnosis, are
indeed likely to account for a substantial delay in tumor forma-
tion. These frequencies reflect ‘‘snapshots’’ of a dynamic
process that involves rapid clearance of senescent cells by the
host immune system (J.R.D. and C.A.S., unpublished data), as
recently reported for a mouse model presenting with senescent
liver cancer cells (Xue et al., 2007). The profound impact on over-
all tumor growth of relatively small steady-state proportions of
cells that exited the cycle is well established in the apoptosis
field and seems to apply to senescent cells in a comparable way.
Of note, cellular and secreted components that delay tumor
manifestation via senescence as shown here do not necessarily
keep operating as tumor constraints during later steps of cancer
progression, because there is ample evidence that both tumor-
associated macrophages and TGF-b can produce deleterious
effects by promoting tumor growth or by exerting tolerogenic
immune effects (Dave et al., 2004; Thomas and Massague,
2005). However, TGF-b1 signaling has just been reported as
a component of the prognostically favorable ‘‘stromal-1’’ signa-
ture in human diffuse large B cell lymphoma (Lenz et al., 2008),
a frequently Myc-activated entity in which we identified here a
subgroup with features highly reminiscent of the presented
mechanism of macrophage-mediated senescence induction
that we genetically dissected in the murine Em-myc model of
aggressive B cell lymphoma.
Furthermore, our findings characterize the Rb-related
Suv39h1-mediated H3K9me3/HP1 heterochromatin mark as a
rather universal and essential downstream effector module of
the senescence program that is still operational in the presence
of constitutive Myc signaling. This chromatin mark is produced
not only by activated oncogenes or DNA damaging chemo-
therapy (Braig et al., 2005; Collado et al., 2005; Michaloglou
et al., 2005), but also by the cytostatic action of secretory
TGF-b. Given the anticancer relevance of cellular senescence,
the now demonstrated inducibility of senescence by a non-
DNA-damaging cytokine opens the exciting perspective to utilize
Suv39h1/H3K9me3-enforcing approaches for future cancer
therapies.EXPERIMENTAL PROCEDURES
Lymphoma Analysis and In Vivo Treatments
The use of human tumor biopsies primarily obtained for the initial diagnosis of
diffuse large B cell lymphoma as anonymous samples was based on informed
patient consent, and was specifically approved by the local ethics commission
of Charite´ - Universita¨tsmedizin Berlin (reference EA4/085/07).
All animal protocols used in this study were approved by the governmental
review board (Landesamt Berlin), and conform to the respective regulatory
standards. Lymphomas with defined genetic defects were generated by inter-
crossing Em-myc transgenic mice with mice carrying loss-of-function alleles at
the Suv39h1, the p53, the INK4a/ARF, the CIP1, or the ATM locus, all in
a C57BL/6 background (Adams et al., 1985; Barlow et al., 1996; Christophorou
et al., 2005; Deng et al., 1995; Jacks et al., 1994; Kamijo et al., 1997; Krimpen-
fort et al., 2001; Peters et al., 2001). Genotyping of the offspring by allele-
specific genomic PCR, monitoring of lymphoma onset, preservation of
snap-frozen or formalin-fixed lymph node tissue and isolation of viable
lymphoma cells, splenic B-lymphocytes (via magnetic bead selection [B cell270 Cancer Cell 17, 262–272, March 16, 2010 ª2010 Elsevier Inc.isolation kit, Miltenyi]), fetal liver cells (FLC), primary peritoneal macrophages
(pMP), or mouse embryo fibroblasts (MEF) were carried out as described
(Davies and Gordon, 2005; Reimann et al., 2007; Schmitt et al., 2002a,
2002b). Where indicated, B cells were prestimulated for 48 hours with 5 mg
lipopolysaccharide (LPS)/ml (from Salmonella enterica; Sigma-Aldrich). Pre-
neoplastic cells were obtained from approximately 30-day-old Em-myc trans-
genic animals devoid of lymph node or spleen enlargement and with no
evidence of leukemia by blood smear analysis. In some experiments, mice
were exposed to specific drug treatments as described in the Supplemental
Experimental Procedures.
Em-myc transgenic FLC as a source of hematopoietic stem cells were ob-
tained to reconstitute (sublethally, i.e., a single 6 or 10 Gy dose of total body
g-irradiation) irradiated nontransgenic recipient mice. FLC, splenic B-lympho-
cytes, isolated lymphoma cells (typically on irradiated NIH3T3 fibroblasts
serving as feeders), macrophages, and MEFs were cultured in liquid medium
or semisolid methylcellulose as described (Schmitt et al., 1999, 2000), and
stably transduced with MSCV-c-Myc-IRES-GFP, MSCV-HA-Suv39h1-puro
(kindly provided as pcDNA3.1-HA-Suv39h1 by A. Leutz), MSCV-bcl2-blastici-
dine, MSCV-bcl2-puro, pBabe-c-MycERTAM-puro (a generous gift from
M. Eilers), or the GFP coencoding retroviruses MSCV-IRES-GFP and
MSCV-TbR-II-ED-IRES-GFP (kindly provided as MSCV-TbR-II-ED-puro by J.
Massague´) (Reimann et al., 2007; Schmitt et al., 1999, 2002b); the C57BL/
6-derived Ana-1 macrophages (kindly provided by L. Varesio) were GFP-trans-
duced via nucleofection (nucleofector kit V, Lonza). In some settings, macro-
phages were treated in vitro with phorbol 12-myristate 13-acetate (PMA;
Sigma), lisinopril, or adriamycin (Sigma) for the indicated times and at the
indicated concentrations.
Analysis of Growth Parameters, Chromosomal Abnormalities,
and DNA Damage
In some experiments, lymphoma cells were exposed in vitro to purified human
TGF-b1 (R&D Systems) at 100 or 1000 pM, or were treated with 1 mM
4-hydroxy-tamoxifen (4-OHT; Sigma-Aldrich) or the equivalent volume of the
ethanol-based solvent, or were incubated with H2O2 (100 mM; Sigma-Aldrich),
or were exposed to the TGF-b R I inhibitor V (SD-208; 500 nM; Calbiochem/
Merck) for the indicated times, or were treated with NAC or caffeine (Sigma-
Aldrich) as stated. Viability and cell numbers were analyzed by trypan blue
dye exclusion, cell-cycle parameters by BrdU and propidium iodide (PI)
staining (Schmitt et al., 1999; Schmitt et al., 2002b). For numeric karyotypic
analysis, at least twelve DAPI stained metaphases were counted per
lymphoma sample (Schmitt et al., 2002b). Cytospin preparations of suspen-
sion cultures for subsequent SA-b-gal analyses or immunostainings, quantifi-
cation of ROS by 20-70-dichlordihydrofluorescein-based flow cytometric
analyses, and quantification of DNA strand breaks in Annexin V-negative cells
(Miltenyi) by the Comet assay were carried out as previously described (Braig
et al., 2005; Reimann et al., 2007). Detection of apoptotic DNA strand breaks
by TUNEL (Roche) staining in paraffin-embedded tissue sections and assess-
ment of SA-b-gal activity at pH 5.5 in cryosections or cytospin preparations of
cell suspensions were carried out as described (Schmitt et al., 2002a; Schmitt
et al., 1999).
Gene Expression Analysis
Genome-wide expression analysis was performed on RNA isolated with Trizol
(Invitrogen) from whole lymph nodes derived from individual lymphoma-
bearing mice and from normal spleen as control, or, in a second set of exper-
iments, from short-term cultured lymphoma cells with and without exposure to
100 pM of human TGF-b1 for 24 hours using a 22.5 K mouse cDNA array. For
RT-PCR analyses, RNA extracts were transcribed into cDNA using Super-
Script reverse transcriptase (Invitrogen) and random hexamers or oligo-dT.
Primer sequences and detailed PCR protocols for the detection of murine
ACE, Suv39h1, Suv39h2, TbRII-ED, and TATA box binding protein (TBP; as
an internal control) transcripts as well as for the RQ-PCR analyses of mouse
CIP1, CTGF, CXCL1, CXCL7, CXCL16, GAPDH, GM-CSF, IGFBP6, IGFBP7,
IL-1a, IL-6, IL-7, INK4b, MCP-4, MIP-3a, MMP2, MMP3, Tgfig, TGF-b1,
TGF-b2, TGF-b3, and VEGF transcripts (using commercially available primers;
Applied Biosystems) are available upon request. For every given sample,
DCt values were determined as the difference between the Ct value of
a specific transcript and the Ct value of GAPDH, serving as the housekeeping
Cancer Cell
Myc Induces Senescence via a DDR and Stromal TGF-bcontrol mRNA, and relative transcript levels (e.g., treated versus untreated)
were then produced based on 2(DDCt) with DDCt = DCttreated  DCtuntreated.
Immunophenotyping by flow cytometry and antigen detection by immuno-
fluorescence, immunohistochemistry, immunoblotting, and immunoprecipita-
tion were carried out as described (Reimann et al., 2007; Schmitt et al., 2002a).
A summary of the methods and the complete list of antibodies used can be
found in the Supplemental Experimental Procedures. Staining intensities of
Smad3-P or PAI-1 in situ were semiquantitatively assessed ( versus +, ++,
or +++; converted into numeric values 0, 1, 2, or 3 to calculate a mean in
some experiments [where a value of around 0.5 would translate into (+)]).
TGF-b1 protein concentrations were also measured by enzyme-linked
immunosorbent assay (Quantikine, R&D Systems) in HCl-activated cell-free
culture supernatant in accordance with the manufacturer’s protocol.
Statistical Evaluation
Tumor onset data reflecting the latency between birth and first-time palpability
of enlarged lymph nodes were compared using the log-rank (Mantel-Cox) test.
Curve fitting analysis was done by linear regression with R2 as the coefficient of
determination. The unpaired t-test was used to compare means and standard
deviations (SD). All quantifications from staining reactions (e.g., immunostain-
ings, TUNEL, or SA-b-gal assays) were carried out by an independent and
blinded second examiner, and reflect at least three samples with at least
200 events counted (typically in more than three different tissue areas) each.
ACCESSION NUMBERS
Details about the cDNA microarray protocols, the specific array design, and
the respective data can be found at http://www.ebi.ac.uk/arrayexpress/ under
accession number E-MEXP-1423 for the first set and E-MEXP-1424 for the
second set of experiments.
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